Clonidine has been used for more than half a century as an antihypertensive drug, to lower blood pressure.
It later
found favour as a treatment for ADHD, drug withdrawal treatment, tobacco withdrawal
treatment and a wide range of psychiatric disorders. Off label usage of Clonidine includes autism.
Until
recently it appeared to researchers to be a centrally acting
α2 adrenergic
agonist, but recent research indicates than instead it is a centrally as an imidazoline
receptor agonist.
This would account for its actions other than lowering blood pressure.
Maybe it is both. The good thing is that
it is centrally acting (i.e. acting on the brain and the CNS) and it does appear
to work.
Adrenergic
Agonist
As a centrally-acting α-adrenergic
receptor agonist, Clonidine has more affinity
for α2 than α1. It
selectively stimulates receptors in the brain that monitor catecholamine (epinephrine, norepinephrine and dopamine) levels in the blood. These
receptors close a negative feedback loop that begins with descending sympathetic
nerves from the brain that controls the production of catecholamines. By
fooling the brain into believing that catecholamine levels are higher
than they really are, clonidine causes the brain to reduce its signals to the
adrenal medulla, which in turn lowers catecholamine production and blood
levels. The result is a lowered heart rate and blood pressure.
Imidazoline
Receptors
There are three classes of imidazoline receptors:- I1
receptor – mediates the sympatho-inhibitory actions of imidazolines to
lower blood pressure
- I2
receptor – an allosteric binding site of monoamine oxidase and is involved in pain
modulation and neuroprotection.
- I3
receptor – regulates insulin secretion
from pancreatic beta cells
L-Monoamine oxidases (MAO)
MAO- A is an enzyme that degrades amine neurotransmitters such as dopamine
(DA), norepinephrine (NE), and serotonin (5-HT).
MAO-B is an enzyme that catalyzes the oxidation of arylalkylamine neurotransmitters, including dopamine (DA).
The differences between the selectivity of the two enzymes are utilized
clinically. MAO- A inhibitors have been
used in the treatment of depression, and MAO-B inhibitors are used in the
treatment of Parkinson's diseaseMAO-B is an enzyme that catalyzes the oxidation of arylalkylamine neurotransmitters, including dopamine (DA).
Selective MAO-B inhibitors preferentially inhibit MAO-B, which mostly
metabolizes DA. If MAO-B is inhibited, then more DA is available for proper
neuronal function, especially in Parkinson's Disease.
Clinical significance
Because of the vital role that MAOs play in the inactivation of
neurotransmitters, MAO dysfunction (too much or too little MAO
activity) is thought to be responsible for a number of psychiatric and
neurological disorders. For example, unusually high or low levels of MAOs in
the body have been associated with schizophrenia, depression, attention deficit disorder, substance abuse, migraines, and
irregular sexual maturation.
MAO inhibitors are one of the major classes of drug prescribed for the
treatment of depression, although they are often last-line treatment due to
risk of the drug's interaction with diet or other drugs. Excessive levels epinephrine,
norepinephrine or dopamine may lead to a hypertensive crisis, and excessive levels of serotonin may lead to serotonin syndrome.
MAO-A inhibitors act as antidepressant and antianxiety agents, whereas
MAO-B inhibitors are used to treat Alzheimer’s and Parkinson’s diseases.
Clonidine in ADHD
In the US,
the FDA has licensed clonidine for use in children with ADHD.
Pediatric doses of clonidine are calculated based on the
child's body weight. Clonidine dosage for ADHD in children is 5 micrograms per
kilogram of body weight per day orally in four divided doses. Children who
require a daily dosage of 0.2 mg usually can use the 0.3 mg trans-dermal patch.
If ADHD is associated with sleep disturbances, low to moderate doses of
clonidine can be taken at bedtime.
Clonidine in
Autism
Not surprisingly, since clonidine is effective in ADHD,
it also shows promise in autism.
Other ADHD drugs, like Ritalin, have problematic side
effects. The US Center
for Disease Control reported in 2012 that an estimated 6.4 million children
ages 4 to 17 had been diagnosed with ADHD at some point, a 53 percent increase
over the past decade. Approximately two-thirds of those currently diagnosed
have been prescribed drugs such as Ritalin or Adderall. Those drugs can help
patients with both mild and severe symptoms, but they can also cause addiction,
anxiety and psychosis. In the UK, it is
suggested that about 3% of children may have ADHD. Drug use is far lower than in the US, but
657,000 prescriptions were written by doctors for drugs like Ritalin in 2012.
There have been studies of clonidine in autism; here a
fairly recent one:-
Perhaps even more interesting is a lively debate among parents who have tried it:-
It does seem to work, but nobody seems to be following it
up.
Clonidine
Stimulation Test
Regular readers will know my interest in TRH and GH. At least there is no doubt about Clonidine’s
effect on GH (growth hormone). If you
want to test pituitary function to see how well GH is being produced, the
standard test is the:-
For those interested in GH, if you were to take
Clonidine, smoke a cigarette and then have your GH measured, the
Endocrinologist would have a surprise.
“These findings suggest that in man nicotinic cholinergic and
adrenergic mechanisms might interact in the stimulation of GH secretion.”
Conclusion
Clonidine looks like another old drug that has been
stumbled upon by somebody doing some off label experimentation. It does seem to have good results in ADHD and
Autism. The good thing is that it is FDA
approved and is available in both oral and time release transdermal forms.
I do not think anybody really understands how it works in
ADHD or other psychiatric
disorders; undoubtedly, there is another, as yet unidentified, mode of action.
For those who want more info:-
Note ulcerative colitis, ADD and even growth delay.